The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder.

ABSTRACT:

Background

Intranasal esketamine demonstrates rapid improvement of depressive symptoms. However, transient adverse effects (dissociation, sedation and dizziness) may occur, which could impact driving performance.

Aims

To evaluate the effects of 84 mg intranasal esketamine on driving performance in unipolar major depressive disorder (MDD) or persistent depressive disorder (PDD) patients.

Methods

The study consisted of two parts. Part A was a single-blind, double-dummy, randomized three-period, cross-over study to compare effects of esketamine versus placebo on next morning driving, 18 ± 2 h post-treatment. Alcohol was administered to demonstrate assay sensitivity. In Part B, same-day driving, 6 ± 0.5 hours post-treatment, was assessed during twice weekly esketamine adm

SUBMITTER: Dijkstra FM 

PROVIDER: S-EPMC9112620 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature